IO Biotech

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

IO Biotech today reported financial results for the third quarter ended September 30, 2024. Read more: https://bit.ly/3AsjI2T #IOBiotech #cancer #financialresults 

IO Biotech is pleased to announce that its Chief Executive Officer, Mai-Britt Zocca, PhD, and Chief Financial Officer, Amy Sullivan, will be attending the following upcoming investor conferences:    Jefferies London Healthcare Conference, London  Date: Wednesday, November 20, 2024    Piper Sandler 36th Annual Healthcare Conference, New York  Date: Tuesday, December 3, 2024, fireside chat at 11:00 am ET  Presenter: Mai-Britt Zocca, PhD, President & CEO    See the full press release for more details: https://bit.ly/48MW5P3   #IOBiotech #cancer #InvestorConferences 

The enthusiasm for our Phase 2 basket study of our lead investigational therapeutic cancer vaccine investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with advanced non-small cell lung cancer and pre-clinical data supporting the future development of the second therapeutic cancer vaccine candidate in our pipeline, IO112, was visible at the #SITC2024 poster presentations yesterday. Thank you, Dr. Riess, for presenting poster #756, and Drs. Martinenaite and Lecoq for presenting poster #1038: https://bit.ly/3UNg1vl #TargetedOncology #ClinicalDevelopment #SITC2024

IO Biotech is pleased to have Jonathan Riess, MD, Director, Thoracic Oncology at the UC Davis Comprehensive Cancer Center and lead author of our poster, 756, presenting updates from the phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced non-small cell lung cancer (NSCLC) as well as both Evelina Martinenaite, PhD, Senior Scientist, and Ines Lecoq, PhD, Scientist of Translational Research at IO Biotech presenting additional Arginase-1 data from the pre-clinical trial of IO112, the second novel T-win® cancer vaccine candidate .   To learn more, visit the poster sessions today, November 9th from 12:15-1:45pm CDT in Exhibit Halls AB.

We’re pleased to announce IO Biotech will share two poster presentations at the SITC annual meeting! One of the posters includes promising data further supporting the potential for the novel investigational therapeutic cancer vaccine, IO102-IO103, in the first-line treatment of advanced non-small cell lung cancer patients. The second poster includes pre-clinical data that supports the future development of the second therapeutic cancer vaccine candidate in our pipeline, IO112. Learn more here: https://bit.ly/4fsVCno

At #SITC2024 this Saturday, Jonathan Riess, MD, Director, Thoracic Oncology at UC Davis Comprehensive Cancer Center and principal investigator of our Phase 2 #ClinicalTrial for NSCLC, will present “A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)”, presentation #756. Also, Evelina Martinenaite, PhD, Senior Scientist, Translational Research, and Inés Lecoq, PhD, Scientist, Translational Research, both at IO Biotech, will present “Immune modulating vaccine against arginase 1 controls tumor growth via modulation of tumor-associated macrophages”, presentation #1038. Stop by Exhibit Halls AB in the George Brown Convention Center, posters #756 and #1038 between 12:15 PM and 1:45 PM CDT on Saturday, November 9th, and talk with Dr. Riess and Drs. Martinenaite and Lecoq about the exciting developments in immune oncology. #SITC2024 #ClinicalDevelopment #ClinicalTrials

Our team is excited to be attending the #SITC2024 annual meeting this week in Houston to connect with fellow professionals focused on cancer immunotherapy - all with the same goal of improving outcomes for people living with cancer. We look forward to discussing our data at our two poster presentations at the meeting: "A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)”, presentation #756, and “Immune modulating vaccine against arginase 1 controls tumor growth via modulation of tumor-associated macrophages”, presentation #1038.

IO Biotech is proud to be a sponsor of a CME session, “Harnessing the Power of Immuno-Modulating Vaccines in Cancer Treatment”, led by faculty members including Jason Luke, MD, University of Pittsburgh School of Medicine, and Geoffrey T Gibney, MD, MedStar Georgetown University Hospital, on Friday, November 8th at 5:30 pm CDT during the SITC 2024 meeting taking place in Houston, Texas.

IO Biotech is proud to support Lung Cancer Awareness Month this November! Lung cancer is a devastating disease that impacts both patients and their loved ones. At IO Biotech, we are dedicated to advancing research to enhance treatment options for people with multiple types of cancer, including lung cancer.   The team is looking forward to presenting encouraging data at #sitc2024 this week from the complete cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in our Phase 2 basket trial of investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy.   For more information about our ongoing efforts and our T-win® technology platform, please visit our website: www.iobiotech.com